Translate Bio develops medicines to treat diseases caused by protein or gene dysfunction. It uses single-stranded oligonucleotides to target the repressive interactions of long non-coding RNA (lncRNA) with specific genes of interest, thereby upregulating mRNA and increasing expression of the encoded protein. The Company is applying its proprietary technology to develop new treatments in several therapeutic areas, with an initial emphasis in the fields of rare genetic disorders, oncology, metabolic diseases and neurodegenerative diseases.